Update on the MiST clinical trial

The Mesothelioma Stratified Therapy (MiST) trial is a British Lung Foundation funded, University of Leicester study – a multi-arm stratified therapy based clinical trial for patients with relapsed mesothelioma.

MiST is a stratified multi-arm phase IIa clinical trial to enable accelerated evaluation of targeted therapies for relapsed malignant mesothelioma. The goal of MiST is to enable acceleration of novel, effective personalised therapy as a basis for improving survival outcomes for patients with mesothelioma. Arm 2 will open from July followed by arms 3 and 4 (arm 1 is now closed to recruitment).

Professor Dean Fennell, Chair of Thoracic Medical Oncology, and Director of the Leicester Mesothelioma Research Programme, University of Leicester and University Hospitals of Leicester NHS Trust said: “The MiST study (arm 1) recruited its first patient in February 2019 and there has been rapid recruitment into the first arm of the study. This trial confirms expectations about the potential of MiST to accelerate personalised drug development in mesothelioma. We look forward to providing new treatment opportunities across the UK for patients, when the three new treatment arms open to recruitment this summer.”

The three new arms will open across multiple centres Newcastle, Manchester, Leicester, Southampton and the Royal Marsden to give nationwide coverage.

Contact info@mesothelioma.uk.com for further details.

Introducing the new Health Companion portal

Working in collaboration with DaSH-Global, a pharmaceutical manufacturing company, we have developed a new digital patient portal known as the ‘Health Companion’. The new system will allow patients to submit data regarding their quality of life and experiences in the...

Join our Asbestos Commercial Club

If you are a business involved in the management of asbestos or the diseases it causes, why not join our Asbestos Commercial Club (MUKACC) to support the vital work that we do? Joining MUKACC can be a great morale booster for your staff, encouraging them to get...

CEO Liz Darlison to speak at the European Asbestos Conference

Mesothelioma UK’s CEO, Liz Darlison, has been confirmed as a speaker at the European Asbestos Forum Conference (EAF). The event will take place from 10-11 November in Amsterdam, in the Netherlands, where she will deliver a talk entitled, Establishing a National...

Mesothelioma National Statistics

The Health and Safety Executive has been publishing statistics on annual mesothelioma deaths in Great Britain on a consistent basis for 50 years. Detailed statistical tables and commentary are available as part of HSE’s National Statistics web pages here. The data...